Achmea Investment Management B.V. Has $4.71 Million Holdings in Illumina, Inc. (NASDAQ:ILMN)

Achmea Investment Management B.V. boosted its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 46.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 35,221 shares of the life sciences company’s stock after buying an additional 11,200 shares during the quarter. Achmea Investment Management B.V.’s holdings in Illumina were worth $4,706,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Vestcor Inc increased its stake in shares of Illumina by 21.9% during the fourth quarter. Vestcor Inc now owns 15,589 shares of the life sciences company’s stock worth $2,083,000 after purchasing an additional 2,796 shares during the period. EverSource Wealth Advisors LLC increased its stake in shares of Illumina by 16.4% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,108 shares of the life sciences company’s stock worth $148,000 after purchasing an additional 156 shares during the period. Sequoia Financial Advisors LLC increased its stake in shares of Illumina by 16.0% during the fourth quarter. Sequoia Financial Advisors LLC now owns 5,733 shares of the life sciences company’s stock worth $766,000 after purchasing an additional 789 shares during the period. Wealthfront Advisers LLC increased its stake in shares of Illumina by 187.0% during the fourth quarter. Wealthfront Advisers LLC now owns 34,464 shares of the life sciences company’s stock worth $4,605,000 after purchasing an additional 22,455 shares during the period. Finally, GC Wealth Management RIA LLC increased its stake in shares of Illumina by 9.5% during the fourth quarter. GC Wealth Management RIA LLC now owns 1,783 shares of the life sciences company’s stock worth $238,000 after purchasing an additional 154 shares during the period. Institutional investors and hedge funds own 89.42% of the company’s stock.

Analysts Set New Price Targets

ILMN has been the topic of a number of recent research reports. TD Cowen lowered Illumina from a “buy” rating to a “hold” rating and lowered their target price for the stock from $177.00 to $140.00 in a research note on Friday, February 7th. Canaccord Genuity Group reduced their price target on Illumina from $135.00 to $115.00 and set a “hold” rating on the stock in a research report on Tuesday. Robert W. Baird reduced their price target on Illumina from $127.00 to $90.00 and set a “neutral” rating on the stock in a research report on Wednesday, March 5th. HSBC downgraded Illumina from a “buy” rating to a “hold” rating and set a $100.00 price target on the stock. in a research report on Friday, February 28th. Finally, Guggenheim reduced their price target on Illumina from $170.00 to $150.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $140.90.

Illumina Trading Up 1.8 %

NASDAQ ILMN opened at $85.60 on Friday. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63. Illumina, Inc. has a twelve month low of $80.18 and a twelve month high of $156.66. The company has a market cap of $13.56 billion, a price-to-earnings ratio of -11.15, a price-to-earnings-growth ratio of 1.60 and a beta of 1.17. The business’s fifty day moving average is $113.52 and its 200 day moving average is $129.88.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. As a group, sell-side analysts expect that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.